Strategic funding Nuevocor has secured around 45M in funding from notable investors including Kurma Partners, Angelini Ventures, EDBI, Boehringer Ingelheim Venture Fund, Coronet Ventures and Highlight Capital, signaling strong investor confidence and potential for expansion partnerships and clinical development collaborations.

Executive leadership Appointment of Monica Shah as Chief Medical Officer and recent board additions including Thierry Abribat and Lola Buono indicates accelerated clinical development and governance readiness, presenting opportunities for high-level advisory collaborations, CRO engagement, and strategic partnerships.

Clinical ambitions The company is preparing to initiate first-in-human studies for NVC-001 targeting LMNA-associated DCM, a high-need genetic cardiomyopathy, suggesting a need for CROs, trial management, imaging, biomarker, and regulatory consultation services.

Global footprint With offices in USA and Singapore and a Singapore headquarters, Nuevocor’s international presence offers cross-border collaboration opportunities, regional partner sourcing, and phased market access strategies across Asia and North America.

Tech and data readiness Leveraging cloud and web technologies in their stack and a mechanobiology platform, the company values digital infrastructure, data management, and analytics capabilities, creating opportunities for cloud services, data security, and collaboration software providers.